Coiled Therapeutics (COIL) 주식 개요코일드 테라퓨틱스는 임상 단계 종양학 회사로 운영되고 있습니다. 자세히 보기COIL 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석재무 데이터를 보고하지 않았습니다.지난 3개월 동안 주가 변동성이 UK 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다(£46M)모든 위험 점검 보기COIL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUK£Current PriceUK£0.11해당 없음내재 할인율Est. Revenue$PastFuture012016201920222025202620282031Revenue UK£1.0Earnings UK£0.2AdvancedSet Fair ValueView all narrativesCoiled Therapeutics plc 경쟁사Hemogenyx PharmaceuticalsSymbol: LSE:HEMOMarket cap: UK£47.5m4basebioSymbol: AIM:4BBMarket cap: UK£81.6mBioventixSymbol: AIM:BVXPMarket cap: UK£87.5mSkinBioTherapeuticsSymbol: AIM:SBTXMarket cap: UK£25.1m가격 이력 및 성과Coiled Therapeutics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가UK£0.1152주 최고가UK£0.3052주 최저가UK£0.068베타01개월 변동45.33%3개월 변동9.00%1년 변동-39.44%3년 변동-83.85%5년 변동-85.47%IPO 이후 변동-83.85%최근 뉴스 및 업데이트공시 • May 28Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026. Location: the offices of reynolds porter chamberlain llp, tower bridge house, st katherines way, e1w 1aa, london United Kingdom공시 • Apr 10Coiled Therapeutics plc Provides Clinical Trial Update on AO-252Coiled Therapeutics plc provided an update on its clinical trial (NCT06136884) evaluating AO-252, a first-in-class TACC3 inhibitor. The transition to a Twice-Daily ("BID") dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate ("CBR"), a significant improvement over the 40% CBR observed in the Once-Daily ("QD") cohort. A particularly notable result has been observed in a leiomyosarcoma patient, who achieved Stable Disease after just two cycles of AO-252, despite having received nine prior lines of therapy. 80% of evaluable patients in the BID cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population. AO-252 continues to demonstrate excellent tolerability with no serious adverse events observed to date. The Maximum Tolerated Dose ("MTD") has not yet been reached, allowing for continued dose escalation to optimise therapeutic impact. Following encouraging signals, the Company is accelerating the transition to targeted dose expansion cohorts in ovarian and prostate cancers, with an enrolment target of 40 patients by Third Quarter 2026. Emerging data confirms AO-252's unique dual-action profile, combining direct cytotoxicity with immune-system activation via the cGAS/STING pathway. On track to complete dose escalation in First Half 2026, with a next-generation formulation to optimise dosing/efficacy and combination therapy protocols scheduled for mid-2026. The ongoing Phase I/II open-label dose escalation study of AO-252 in patients with advanced solid tumours has enrolled 31 patients to date, of whom 25 are evaluable for safety and dose-limiting toxicity ("DLT") assessment and 21 are evaluable for efficacy. Dose escalation remains on track for completion in First Half 2026. The transition to a BID dosing regimen in Cohort 4b has produced a clinically meaningful step-change in disease control. An 80% CBR has been observed in Cohort 4b, compared to 40% in the QD Cohort 4a, reflecting the importance of sustained drug exposure at therapeutic levels. Four out of five evaluable patients in Cohort 4b demonstrated tumour stabilisation or regression. Notably, treatment duration in this cohort has exceeded six months, substantially longer than the two to three months typically achieved with salvage therapy in these heavily pretreated populations (median of five prior lines of therapy). AO-252 appears to possess meaningful immune-modulatory activity, consistent with its known ability to stimulate the cGAS/STING pathway and activate dendritic cells and M1 macrophages. This positions AO-252 as a potentially rare small molecule capable of directly activating the immune system in addition to its direct anti-tumour cytotoxic effects. The Company believes this immune-modulatory property could significantly enhance AO-252's utility in combination regimens, including with immuno-oncology agents, and broadens its differentiated therapeutic profile and commercial appeal. Analysis of clinical pharmacokinetic data has identified distinct drug exposure variances between male and female patients. This finding is being incorporated into refined dose modelling to ensure optimal efficacy and safety parameters as the programme advances. A dedicated sub-arm of Cohort 4b is currently evaluating the impact of food on AO-252 absorption, with efficacy and pharmacokinetic data expected in late Second Quarter 2026. In parallel, a next-generation formulation of AO-252 is on track for introduction in mid-2026. The refined formulation is designed to further improve drug exposure to attain maximal efficacy and duration of therapy. Leveraging AO-252's immune-modulatory backbone and its demonstrated synergy with immuno-oncology and antibody-drug conjugate agents in preclinical studies, the Company is actively developing a combination therapy protocol. Study initiation is targeted for Third Quarter 2026, with a view to exploring AO-252's potential in multi-agent oncology regimens. The Company is preparing to transition from the current broad dose escalation strategy to targeted dose expansion cohorts focused primarily on ovarian and prostate cancer indications where early clinical signals have been particularly encouraging and where commercial interest from large pharmaceutical companies is strong. The Company is targeting enrolment of 40 patients by Third Quarter 2026. Strategic engagement with Key Opinion Leaders (KOLs) continues to refine the clinical development strategy, ensuring that study design and patient selection remain aligned with the emerging scientific understanding of AO-252's unique mechanism of action. Key milestones for 2026 are summarised below: First Half 2026: Completion of Phase I dose escalation; preliminary proof-of-concept safety and efficacy data from dose escalation phase. Late Second Quarter 2026: Food-effect sub-arm data from Cohort 4b pharmacokinetic study. Mid-2026: Introduction of refined next-generation formulation of AO-252. Third Quarter 2026: Initiation of combination therapy protocol study; 40-patient enrolment target reached. Second Half 2026: Comprehensive expansion cohort efficacy and safety data readouts in ovarian and prostate cancer; potential Phase II registrational trial planning and commercial discussions.더 많은 업데이트 보기Recent updates공시 • May 28Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026. Location: the offices of reynolds porter chamberlain llp, tower bridge house, st katherines way, e1w 1aa, london United Kingdom공시 • Apr 10Coiled Therapeutics plc Provides Clinical Trial Update on AO-252Coiled Therapeutics plc provided an update on its clinical trial (NCT06136884) evaluating AO-252, a first-in-class TACC3 inhibitor. The transition to a Twice-Daily ("BID") dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate ("CBR"), a significant improvement over the 40% CBR observed in the Once-Daily ("QD") cohort. A particularly notable result has been observed in a leiomyosarcoma patient, who achieved Stable Disease after just two cycles of AO-252, despite having received nine prior lines of therapy. 80% of evaluable patients in the BID cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population. AO-252 continues to demonstrate excellent tolerability with no serious adverse events observed to date. The Maximum Tolerated Dose ("MTD") has not yet been reached, allowing for continued dose escalation to optimise therapeutic impact. Following encouraging signals, the Company is accelerating the transition to targeted dose expansion cohorts in ovarian and prostate cancers, with an enrolment target of 40 patients by Third Quarter 2026. Emerging data confirms AO-252's unique dual-action profile, combining direct cytotoxicity with immune-system activation via the cGAS/STING pathway. On track to complete dose escalation in First Half 2026, with a next-generation formulation to optimise dosing/efficacy and combination therapy protocols scheduled for mid-2026. The ongoing Phase I/II open-label dose escalation study of AO-252 in patients with advanced solid tumours has enrolled 31 patients to date, of whom 25 are evaluable for safety and dose-limiting toxicity ("DLT") assessment and 21 are evaluable for efficacy. Dose escalation remains on track for completion in First Half 2026. The transition to a BID dosing regimen in Cohort 4b has produced a clinically meaningful step-change in disease control. An 80% CBR has been observed in Cohort 4b, compared to 40% in the QD Cohort 4a, reflecting the importance of sustained drug exposure at therapeutic levels. Four out of five evaluable patients in Cohort 4b demonstrated tumour stabilisation or regression. Notably, treatment duration in this cohort has exceeded six months, substantially longer than the two to three months typically achieved with salvage therapy in these heavily pretreated populations (median of five prior lines of therapy). AO-252 appears to possess meaningful immune-modulatory activity, consistent with its known ability to stimulate the cGAS/STING pathway and activate dendritic cells and M1 macrophages. This positions AO-252 as a potentially rare small molecule capable of directly activating the immune system in addition to its direct anti-tumour cytotoxic effects. The Company believes this immune-modulatory property could significantly enhance AO-252's utility in combination regimens, including with immuno-oncology agents, and broadens its differentiated therapeutic profile and commercial appeal. Analysis of clinical pharmacokinetic data has identified distinct drug exposure variances between male and female patients. This finding is being incorporated into refined dose modelling to ensure optimal efficacy and safety parameters as the programme advances. A dedicated sub-arm of Cohort 4b is currently evaluating the impact of food on AO-252 absorption, with efficacy and pharmacokinetic data expected in late Second Quarter 2026. In parallel, a next-generation formulation of AO-252 is on track for introduction in mid-2026. The refined formulation is designed to further improve drug exposure to attain maximal efficacy and duration of therapy. Leveraging AO-252's immune-modulatory backbone and its demonstrated synergy with immuno-oncology and antibody-drug conjugate agents in preclinical studies, the Company is actively developing a combination therapy protocol. Study initiation is targeted for Third Quarter 2026, with a view to exploring AO-252's potential in multi-agent oncology regimens. The Company is preparing to transition from the current broad dose escalation strategy to targeted dose expansion cohorts focused primarily on ovarian and prostate cancer indications where early clinical signals have been particularly encouraging and where commercial interest from large pharmaceutical companies is strong. The Company is targeting enrolment of 40 patients by Third Quarter 2026. Strategic engagement with Key Opinion Leaders (KOLs) continues to refine the clinical development strategy, ensuring that study design and patient selection remain aligned with the emerging scientific understanding of AO-252's unique mechanism of action. Key milestones for 2026 are summarised below: First Half 2026: Completion of Phase I dose escalation; preliminary proof-of-concept safety and efficacy data from dose escalation phase. Late Second Quarter 2026: Food-effect sub-arm data from Cohort 4b pharmacokinetic study. Mid-2026: Introduction of refined next-generation formulation of AO-252. Third Quarter 2026: Initiation of combination therapy protocol study; 40-patient enrolment target reached. Second Half 2026: Comprehensive expansion cohort efficacy and safety data readouts in ovarian and prostate cancer; potential Phase II registrational trial planning and commercial discussions.주주 수익률COILGB BiotechsGB 시장7D-7.2%-2.3%-0.3%1Y-39.4%21.4%18.3%전체 주주 수익률 보기수익률 대 산업: COIL은 지난 1년 동안 21.4%의 수익을 기록한 UK Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: COIL은 지난 1년 동안 18.3%를 기록한 UK 시장보다 저조한 성과를 냈습니다.주가 변동성Is COIL's price volatile compared to industry and market?COIL volatilityCOIL Average Weekly Movement12.4%Biotechs Industry Average Movement9.2%Market Average Movement5.7%10% most volatile stocks in GB Market11.8%10% least volatile stocks in GB Market3.1%안정적인 주가: COIL의 주가는 지난 3개월 동안 UK 시장보다 변동성이 컸습니다.시간에 따른 변동성: COIL의 주간 변동성(12%)은 지난 1년 동안 안정적이었지만 UK 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트n/an/aSridhar Vempatiwww.coiledtx.com/코일드 테라퓨틱스는 임상 단계 종양학 회사로 운영되고 있습니다. 이 회사는 뉴저지 에디슨에 본사를 두고 있습니다.더 보기Coiled Therapeutics plc 기초 지표 요약Coiled Therapeutics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?COIL 기초 통계시가총액UK£46.42m순이익 (TTM)UK£0매출 (TTM)n/an/a주가수익비율(P/E)n/a주가매출비율(P/S)COIL는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표COIL 손익계산서 (TTM)매출UK£0매출원가UK£0총이익UK£0기타 비용UK£0순이익UK£0최근 보고된 실적해당 없음다음 실적 발표일해당 없음주당순이익(EPS)0총이익률0.00%순이익률0.00%부채/자본 비율0.0%COIL의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/29 17:58종가2026/05/29 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Coiled Therapeutics plc는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • May 28Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026. Location: the offices of reynolds porter chamberlain llp, tower bridge house, st katherines way, e1w 1aa, london United Kingdom
공시 • Apr 10Coiled Therapeutics plc Provides Clinical Trial Update on AO-252Coiled Therapeutics plc provided an update on its clinical trial (NCT06136884) evaluating AO-252, a first-in-class TACC3 inhibitor. The transition to a Twice-Daily ("BID") dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate ("CBR"), a significant improvement over the 40% CBR observed in the Once-Daily ("QD") cohort. A particularly notable result has been observed in a leiomyosarcoma patient, who achieved Stable Disease after just two cycles of AO-252, despite having received nine prior lines of therapy. 80% of evaluable patients in the BID cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population. AO-252 continues to demonstrate excellent tolerability with no serious adverse events observed to date. The Maximum Tolerated Dose ("MTD") has not yet been reached, allowing for continued dose escalation to optimise therapeutic impact. Following encouraging signals, the Company is accelerating the transition to targeted dose expansion cohorts in ovarian and prostate cancers, with an enrolment target of 40 patients by Third Quarter 2026. Emerging data confirms AO-252's unique dual-action profile, combining direct cytotoxicity with immune-system activation via the cGAS/STING pathway. On track to complete dose escalation in First Half 2026, with a next-generation formulation to optimise dosing/efficacy and combination therapy protocols scheduled for mid-2026. The ongoing Phase I/II open-label dose escalation study of AO-252 in patients with advanced solid tumours has enrolled 31 patients to date, of whom 25 are evaluable for safety and dose-limiting toxicity ("DLT") assessment and 21 are evaluable for efficacy. Dose escalation remains on track for completion in First Half 2026. The transition to a BID dosing regimen in Cohort 4b has produced a clinically meaningful step-change in disease control. An 80% CBR has been observed in Cohort 4b, compared to 40% in the QD Cohort 4a, reflecting the importance of sustained drug exposure at therapeutic levels. Four out of five evaluable patients in Cohort 4b demonstrated tumour stabilisation or regression. Notably, treatment duration in this cohort has exceeded six months, substantially longer than the two to three months typically achieved with salvage therapy in these heavily pretreated populations (median of five prior lines of therapy). AO-252 appears to possess meaningful immune-modulatory activity, consistent with its known ability to stimulate the cGAS/STING pathway and activate dendritic cells and M1 macrophages. This positions AO-252 as a potentially rare small molecule capable of directly activating the immune system in addition to its direct anti-tumour cytotoxic effects. The Company believes this immune-modulatory property could significantly enhance AO-252's utility in combination regimens, including with immuno-oncology agents, and broadens its differentiated therapeutic profile and commercial appeal. Analysis of clinical pharmacokinetic data has identified distinct drug exposure variances between male and female patients. This finding is being incorporated into refined dose modelling to ensure optimal efficacy and safety parameters as the programme advances. A dedicated sub-arm of Cohort 4b is currently evaluating the impact of food on AO-252 absorption, with efficacy and pharmacokinetic data expected in late Second Quarter 2026. In parallel, a next-generation formulation of AO-252 is on track for introduction in mid-2026. The refined formulation is designed to further improve drug exposure to attain maximal efficacy and duration of therapy. Leveraging AO-252's immune-modulatory backbone and its demonstrated synergy with immuno-oncology and antibody-drug conjugate agents in preclinical studies, the Company is actively developing a combination therapy protocol. Study initiation is targeted for Third Quarter 2026, with a view to exploring AO-252's potential in multi-agent oncology regimens. The Company is preparing to transition from the current broad dose escalation strategy to targeted dose expansion cohorts focused primarily on ovarian and prostate cancer indications where early clinical signals have been particularly encouraging and where commercial interest from large pharmaceutical companies is strong. The Company is targeting enrolment of 40 patients by Third Quarter 2026. Strategic engagement with Key Opinion Leaders (KOLs) continues to refine the clinical development strategy, ensuring that study design and patient selection remain aligned with the emerging scientific understanding of AO-252's unique mechanism of action. Key milestones for 2026 are summarised below: First Half 2026: Completion of Phase I dose escalation; preliminary proof-of-concept safety and efficacy data from dose escalation phase. Late Second Quarter 2026: Food-effect sub-arm data from Cohort 4b pharmacokinetic study. Mid-2026: Introduction of refined next-generation formulation of AO-252. Third Quarter 2026: Initiation of combination therapy protocol study; 40-patient enrolment target reached. Second Half 2026: Comprehensive expansion cohort efficacy and safety data readouts in ovarian and prostate cancer; potential Phase II registrational trial planning and commercial discussions.
공시 • May 28Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026Coiled Therapeutics plc, Annual General Meeting, Jun 24, 2026. Location: the offices of reynolds porter chamberlain llp, tower bridge house, st katherines way, e1w 1aa, london United Kingdom
공시 • Apr 10Coiled Therapeutics plc Provides Clinical Trial Update on AO-252Coiled Therapeutics plc provided an update on its clinical trial (NCT06136884) evaluating AO-252, a first-in-class TACC3 inhibitor. The transition to a Twice-Daily ("BID") dosing regimen (Cohort 4b) has delivered an 80% Clinical Benefit Rate ("CBR"), a significant improvement over the 40% CBR observed in the Once-Daily ("QD") cohort. A particularly notable result has been observed in a leiomyosarcoma patient, who achieved Stable Disease after just two cycles of AO-252, despite having received nine prior lines of therapy. 80% of evaluable patients in the BID cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population. AO-252 continues to demonstrate excellent tolerability with no serious adverse events observed to date. The Maximum Tolerated Dose ("MTD") has not yet been reached, allowing for continued dose escalation to optimise therapeutic impact. Following encouraging signals, the Company is accelerating the transition to targeted dose expansion cohorts in ovarian and prostate cancers, with an enrolment target of 40 patients by Third Quarter 2026. Emerging data confirms AO-252's unique dual-action profile, combining direct cytotoxicity with immune-system activation via the cGAS/STING pathway. On track to complete dose escalation in First Half 2026, with a next-generation formulation to optimise dosing/efficacy and combination therapy protocols scheduled for mid-2026. The ongoing Phase I/II open-label dose escalation study of AO-252 in patients with advanced solid tumours has enrolled 31 patients to date, of whom 25 are evaluable for safety and dose-limiting toxicity ("DLT") assessment and 21 are evaluable for efficacy. Dose escalation remains on track for completion in First Half 2026. The transition to a BID dosing regimen in Cohort 4b has produced a clinically meaningful step-change in disease control. An 80% CBR has been observed in Cohort 4b, compared to 40% in the QD Cohort 4a, reflecting the importance of sustained drug exposure at therapeutic levels. Four out of five evaluable patients in Cohort 4b demonstrated tumour stabilisation or regression. Notably, treatment duration in this cohort has exceeded six months, substantially longer than the two to three months typically achieved with salvage therapy in these heavily pretreated populations (median of five prior lines of therapy). AO-252 appears to possess meaningful immune-modulatory activity, consistent with its known ability to stimulate the cGAS/STING pathway and activate dendritic cells and M1 macrophages. This positions AO-252 as a potentially rare small molecule capable of directly activating the immune system in addition to its direct anti-tumour cytotoxic effects. The Company believes this immune-modulatory property could significantly enhance AO-252's utility in combination regimens, including with immuno-oncology agents, and broadens its differentiated therapeutic profile and commercial appeal. Analysis of clinical pharmacokinetic data has identified distinct drug exposure variances between male and female patients. This finding is being incorporated into refined dose modelling to ensure optimal efficacy and safety parameters as the programme advances. A dedicated sub-arm of Cohort 4b is currently evaluating the impact of food on AO-252 absorption, with efficacy and pharmacokinetic data expected in late Second Quarter 2026. In parallel, a next-generation formulation of AO-252 is on track for introduction in mid-2026. The refined formulation is designed to further improve drug exposure to attain maximal efficacy and duration of therapy. Leveraging AO-252's immune-modulatory backbone and its demonstrated synergy with immuno-oncology and antibody-drug conjugate agents in preclinical studies, the Company is actively developing a combination therapy protocol. Study initiation is targeted for Third Quarter 2026, with a view to exploring AO-252's potential in multi-agent oncology regimens. The Company is preparing to transition from the current broad dose escalation strategy to targeted dose expansion cohorts focused primarily on ovarian and prostate cancer indications where early clinical signals have been particularly encouraging and where commercial interest from large pharmaceutical companies is strong. The Company is targeting enrolment of 40 patients by Third Quarter 2026. Strategic engagement with Key Opinion Leaders (KOLs) continues to refine the clinical development strategy, ensuring that study design and patient selection remain aligned with the emerging scientific understanding of AO-252's unique mechanism of action. Key milestones for 2026 are summarised below: First Half 2026: Completion of Phase I dose escalation; preliminary proof-of-concept safety and efficacy data from dose escalation phase. Late Second Quarter 2026: Food-effect sub-arm data from Cohort 4b pharmacokinetic study. Mid-2026: Introduction of refined next-generation formulation of AO-252. Third Quarter 2026: Initiation of combination therapy protocol study; 40-patient enrolment target reached. Second Half 2026: Comprehensive expansion cohort efficacy and safety data readouts in ovarian and prostate cancer; potential Phase II registrational trial planning and commercial discussions.
